Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
INT-101-01
A Study of YL201 in Patients With Advanced Solid Tumors
- NCT05434234 ↗
- Recruiting
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Focused
We haven't built an HCP commentary report on INT-101-01 (YL201 and YL201 and atezolizumab in Advanced Solid Tumor) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on INT-101-01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1A/1B, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- YL201; YL201; YL201 and atezolizumab
- Arms
- Dose escalation · Experimental
- Dose expansion · Experimental
- Dose Selection · Experimental
- Enrollment
- 312 (estimated)
- Primary outcomes
- Evaluate the occurrence of DLTs during the first cycle in Part 1
- Evaluate the AEs in Part 2 as characterized by type, frequency, severity, timing, seriousness and relationship to study treatment
- Evaluate the prostate-specific antigen (PSA) response rate for patients with prostate cancer in Part 2
- Evaluate the objective response rate (ORR) for patients with solid tumors other than prostate cancer in Part 2, assessed using RECIST version 1.1
- Laboratory abnormalities as characterized by type, frequency, severity, and timing in Part 2
- Incidence, nature, and severity of AEs graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V5.0 in Part 3
- Nature and frequency of dose-limiting toxicities (DLTs), incidence, nature, and severity of laboratory abnormalities in Part 3
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Start
- May 25, 2022
- Primary completion
- Apr 6, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05434234 · updated Jun 22, 2026
Publications
linked from the registry- Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng X, Fan Y, Fu S, Wu L, Zheng Y, Liu J, Liu Z, Zhuang W, Rosen S, Qu S, Li B, Li M, Zhao Y, Yang S, Ji Y, Sommerhalder D, Luo S, Yang K, Li J, Lv D, Zhang P, Zhao Y, Hong S, Zhang Y, Zhao S, Chin S, Zhang X, Lian W, Cai J, Xue T, Zhang L, Zhao H. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial. Nat Med. 2025 Jun;31(6):1949-1957. doi: 10.1038/s41591-025-03600-2. Epub 2025 Mar 13. PubMed 40082695